Menu
My Activity Hub
Podcasts
Videos
Pricing
Feedback
Tutoring
Sign Up
Log In
My Activity Hub
Podcasts
Videos
How it works
Pricing
Tutoring
Sign Up
Log In
CME
Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
0 secs; November 26, 2024
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
0 secs; November 26, 2024
Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies
0 secs; November 26, 2024
Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
0 secs; November 26, 2024
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
0 secs; November 26, 2024
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
0 secs; November 26, 2024
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
0 secs; November 26, 2024
Insights from global key opinion leaders on optimizing patient care in NSCLC
0 secs; November 26, 2024
FCS and SHTG: Are We Meeting the Need?
0 secs; November 21, 2024
Current Experiences in Identifying and Treating Itch in Patients on Hemodialysis
0 secs; November 20, 2024
Optimizing Outcomes in Patients With IgAN: Novel Therapies and Evolving Guidelines
0 secs; November 20, 2024
Advances in the Treatment of PBC: Part 1
0 secs; November 07, 2024
Advances in the Treatment of PBC: Part 2
0 secs; November 07, 2024
Does Your Patient Have PBC?
0 secs; November 07, 2024
Don't Forget, There's a Sleepy Patient Behind Those Numbers
0 secs; November 07, 2024
Don't Forget, There's an Itchy Patient Behind Those Numbers
0 secs; November 07, 2024
Initiating Second-Line Therapy: What, When, and Then What?
0 secs; November 07, 2024
PBC Is Risky Business
0 secs; November 07, 2024
PBC Target Practice: Normalization Is the New Norm
0 secs; November 07, 2024
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
0 secs; October 30, 2024
Cardiorenal Collaboration: Optimizing Multidisciplinary Care in the CvRM Patient
0 secs; October 22, 2024
Breathing Through the Burden of COPD
0 secs; October 17, 2024
Diagnosing COPD: From Symptoms to Assessment & the 2024 GOLD Standards
0 secs; October 17, 2024
Going Beyond Today’s Assessments to Confirm COPD, Are Biomarkers Key?
0 secs; October 17, 2024
Insights to Pharmaceutical Approaches in COPD
0 secs; October 17, 2024
Molecular Mechanisms of COPD
0 secs; October 17, 2024
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
0 secs; October 17, 2024
Putting Theory Into Practice: Mastering Management of COPD
0 secs; October 17, 2024
Unveiling the Latest Advancements in CKD-Associated Pruritus Care
0 secs; October 17, 2024
Partnering for Progress: A Case Study in Patient-Centered Hyperkalemia Management
0 secs; October 16, 2024
Pulmonary Hypertension for Advanced Practice Providers: Risk Stratification and Diagnosis to Enhance Quality of Care and Outcomes
0 secs; October 16, 2024
AAD Treatment Evolution: The Future of Emerging Therapies
0 secs; October 14, 2024
Building Better Strategies: Incorporating New AAD Treatments Into Clinical Practice
0 secs; October 14, 2024
Burden Beyond the Patient: AAD's Impact on Patients and Caregivers
0 secs; October 14, 2024
Caregiver Screening Tools for Agitation in Alzheimer’s Disease
0 secs; October 14, 2024
Conversations With Patients About PTSD, Screening, and Referral
0 secs; October 14, 2024
Early Warning: Clinical Signs of AAD Every PCP and Caregiver Should Know
0 secs; October 14, 2024
Inconsistent Outcomes: How Ignoring Guidelines Leads to Unpredictable Results
0 secs; October 14, 2024
Innovative Therapeutics: How Pathophysiology Guides New AAD Treatment Development
0 secs; October 14, 2024
Limitations of Current Treatments: FDA-Approved and Off-Label Approaches
0 secs; October 14, 2024
Mapping the Mind: The Pathophysiology That Drives AAD
0 secs; October 14, 2024
Modeling Activity: Quality Conversations With Patients About Suboptimal Management of PTSD Symptoms and Emerging Treatment Options
0 secs; October 14, 2024
Navigating Therapy: Exploring FDA-Approved Treatments for Effective AAD Care
0 secs; October 14, 2024
Pathophysiology and Pharmacologic Rationale of Emerging Agents for the Treatment of PTSD
0 secs; October 14, 2024
Patient-Centric Approaches to Optimizing Outcomes in AAD: Case Review
0 secs; October 14, 2024
Prevalence and Burden of PTSD in Women: Focus on Factors That Affect Patient Presentation, Such as Race, Risk Factors, Stigma, and Other Drivers
0 secs; October 14, 2024
Proactive Screening: Essential Tools for Diagnosing AAD Quickly
0 secs; October 14, 2024
Proactively Uncovering Potential Traumatic Experiences Linked to Patient Psychiatric Symptoms in Women
0 secs; October 14, 2024
Profile and Role of Emerging Treatment Options: MOA, Safety and Efficacy, and Identifying the Patients Who May Benefit
0 secs; October 14, 2024
Role of PCP & Ob-Gyn With Women at Risk for PTSD: Recognition, Screening, and Referral
0 secs; October 14, 2024
Safety, Efficacy, and Black Box Warnings: Challenges Associated With Off-Label Treatments of AAD
0 secs; October 14, 2024
Setting the Stage: Unmet Needs in the Treatment of Women With PTSD
0 secs; October 14, 2024
Team Approach: Enhancing Collaboration in AAD Management
0 secs; October 14, 2024
Advancing Cystic Fibrosis:Â Addressing Disparities, Challenging Perceptions, and Innovating Patient-Centered Care
0 secs; October 10, 2024
Bridging Distances in PAH: Bringing Best Practices to the People Through Telementoring
0 secs; October 10, 2024
Updates From the 7th World Symposium Task Force
0 secs; October 10, 2024
Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
0 secs; October 03, 2024
Navigating COPD: From Symptom Recognition to Emerging Treatment Strategies
0 secs; October 03, 2024
Biomarkers of the Storm: Decoding IRI’s Signature
0 secs; October 01, 2024
The Evolving Role of MET TKIs in NSCLC
0 secs; October 01, 2024
The Heart’s Aftermath: IRI’s Impact on Cardiac Morbidity & Mortality
0 secs; October 01, 2024
Unveiling the Reperfusion Paradox
0 secs; October 01, 2024
What’s on the Horizon for IRI Management?
0 secs; October 01, 2024
ARVO Recap: What’s New in TED
0 secs; September 29, 2024
Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer
0 secs; September 29, 2024
Diagnostic Challenges of TED: What Endocrinologists Need to Know
0 secs; September 29, 2024
Diagnostic Challenges of TED: What Eye Care Specialists Need to Know
0 secs; September 29, 2024
Diagnostic Challenges of TED: What General Eye Care Providers Need to Know
0 secs; September 29, 2024
TED: Clinical Trials Spotlight
0 secs; September 29, 2024
TED: Current Treatments, Current Challenges
0 secs; September 29, 2024
The Burden of TED
0 secs; September 29, 2024
The Future of TED
0 secs; September 29, 2024
Underlying Mediators of Immune Dysregulation in TED
0 secs; September 29, 2024
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
0 secs; September 24, 2024
Mastering the Complexity of AML Treatment: A Multidimensional Approach to Diagnosis, Therapy, and Side Effect Management
0 secs; September 24, 2024
Phase 3 study results of plozasiran in patients with FCS
0 secs; September 23, 2024
Noncovalent BTK Inhibitors: New Targeted Options for Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
0 secs; September 23, 2024
Warm Autoimmune Hemolytic Anemia: How Antibody-Based Therapies Are Revolutionizing Its Management
0 secs; September 17, 2024
A Practical Guide to Prescribing in HF
0 secs; September 15, 2024
Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression
0 secs; September 15, 2024
HF Management for Patients with Comorbid Conditions
0 secs; September 15, 2024
Level Up Your Skills: Tailoring Management of HF
0 secs; September 15, 2024
Partnering with Patients: Building Effective Communication and Support in HF Care
0 secs; September 15, 2024
Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting
0 secs; September 12, 2024
Diversity in HER2 Expression Among Gynecologic Cancers
0 secs; August 29, 2024
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
0 secs; August 29, 2024
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
0 secs; August 29, 2024
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
0 secs; August 29, 2024
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
0 secs; August 29, 2024
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
0 secs; August 29, 2024
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
0 secs; August 29, 2024
Significance of HER2 Expression in Solid Tumors
0 secs; August 29, 2024
Combination Therapy for CLL: What Evidence Do We Have?
0 secs; August 15, 2024
Combination Therapy in CLL: Identifying the Right Patient for the Right Treatment Approach
0 secs; August 15, 2024
Fixed-Duration Therapy in the Relapsed/Refractory CLL Setting
0 secs; August 15, 2024
Fixed-Duration vs Continuous-Dosing Approaches in CLL: Impact on QoL and Toxicity Risk
0 secs; August 15, 2024
Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability
0 secs; August 15, 2024
MRD Testing to Guide Treatment Considerations in CLL
0 secs; August 15, 2024
Mutational Testing to Guide Therapy in CLL: Why and When
0 secs; August 15, 2024
Overcoming Disease Progression in CLL: Evidence-Based Re-treatment Considerations
0 secs; August 15, 2024
Click here to see more
‹ Prev
1
2
3
4
5
6
7
8
Next ›
